During human pregnancy, paternally inherited antigens expressed by the fetal-placental unit can elicit expansion of antigen-specific CD8+ T cells. These cells can persist for years as memory T cells, but their effects on long-term maternal health are unknown. Shared placenta/tumor-associated antigens are expressed by placenta and tumors, but are minimally expressed or absent in normal adult tissues. We hypothesized that maternal T cells elicited against these antigens can alter risk of cancers expressing the same antigen after pregnancy, and tested this in mice using chicken ovalbumin (OVA) as a surrogate shared placenta/tumor antigen. Hemizygous OVA transgenic males were bred to wild-type C57BL/6 females (H2b haplotype) such that the fetuses inherited and expressed OVA. Maternal OVA/H2K b -specific CD8+ T cells became detectable during gestation, and persisted in some animals for up to 24 weeks. To determine whether these cells might influence growth of OVA-expressing tumors in OVA-bred females, E.G7-OVA thymoma cells were inoculated subcutaneously in OVA-bred, wild-type bred, and virgin females, and monitored for growth. OVA-bred mice had prolonged survival as compared to virgin mice and the progression of tumors was delayed in comparison to wild-type bred and virgin females. Thus, paternally inherited OVA antigen elicited a CD8+ T cell response during pregnancy that was associated with delayed growth of OVAexpressing tumors following pregnancy. These data suggest a possible role of antigen-specific T cells in protecting parous females against tumors bearing shared placenta/tumor antigens.
Introduction
Cancer is one of the main public health concerns and the second leading cause of death in the United States following cardiovascular disease [1] . Among women in the United States alone, the estimated number of deaths due to new cancer in 2015 was nearly 600,000 [2] . Despite this enormous public health burden, cancer death rates have been continuously decreasing for the past two decades [1] , mainly due to advances in screening, early detection, treatment, and preventative health measures. Additionally, the pathophysiological mechanisms that influence cancer risk, such as environmental exposures together with genetic and epigenetic factors, are becoming increasingly understood.
Pregnancy is one of the most protective physiological factors impacting risk of hormone-dependent cancers, most notably breast cancer [3, 4] . The leading explanation underlying this effect is that gestational hormones promote terminal differentiation of epithelial stem cells within the alveoli and ducts of the mammary gland [3] . Several studies have also shown an association between parity and reduced cancer-risk for hormone-independent cancers [5, 6] . However, the effects of pregnancy-associated hormones on cancer are not always consistent or straightforward, and vary with the animal model, timing of treatments, and doses of hormones [3, 7] . Also, treatment with progesterone alone, or long-term estrogen and progesterone, promotes, rather than impedes, breast cancer progression [3, 7] . Thus, it is likely that other factors specific to pregnancy in addition to hormones are at play in influencing risk of cancer in parous women.
Pregnancy has complex and profound influences on the maternal immune system. On one hand, maternal immune system needs to maintain the ability to overcome infections acquired prior to or during pregnancy. On the other hand, the maternal immune system must not only tolerate the semiallogeneic fetus, but also facilitate placentation and growth of the fetus. Surprisingly, women carrying male fetuses become sensitized to immunodominant epitopes of paternally inherited antigens that are expressed by fetal tissues and placenta, as evidenced by the presence of fetal antigen-specific peripheral blood cytotoxic T cells in pregnant women [8] [9] [10] . Antigens that can, in healthy pregnancies in women, prime the maternal immune system include the autosomally encoded minor histocompatibility antigens HMHA1 (also called HA-1), MYO1G (also called HA-2), and the Y-chromosome-encoded SMCY (also called) HY antigen [8, [10] [11] [12] . These antigens are all expressed in the placenta, which, because of its hemochorial anatomy, is awash in maternal blood throughout the majority of pregnancy, and is therefore an important source of fetal antigen exposure to the mother [13] . Intriguingly, maternal T cells recognizing these antigens possess a memory phenotype and can be reactivated in vitro to secrete cytokines and kill target cells. Furthermore, these maternal T cells can persist for decades in maternal blood. These cells do no harm to the growing fetus during a normal pregnancy or during subsequent normal pregnancies because multiple mechanisms are in place to ensure that these cells cannot reject the fetus. However, the physiological and pathological effects of the long-term presence of these cells in parous women are unknown.
Fetal-placental proteins that are antigenic to the mother may not be restricted to the major and minor histocompatibility antigens deriving from the paternal genome, but could also include placentaspecific antigens. One such group of antigens could be a subset of tumor-associated antigens that are also expressed by the fetalplacental unit [14] [15] [16] . In normal adult tissues, these antigens are minimally expressed or unexpressed, while in cancers, their expression can be widespread. Antigens common to the shared placenta and tumors include the cancer-testis antigens CTA1B/NY-ESO-1, PLAC1, MAGEA3, and MAGEA4, as well as the oncofetal antigen trophoblast glycoprotein (also called 5T4 or Wnt-activated inhibitory factor 1/WAIF1) [14] [15] [16] . In cancer patients, these antigens can elicit spontaneous cellular and humoral immune responses, which may indicate favorable prognoses; further, they have garnered much interest as immunotherapeutic targets. Interestingly, these antigens are expressed amply by the syncytiotrophoblast and/or cytotrophoblast layers of the human placenta [15, 16] ; but whether they elicit maternal immunity during pregnancy is unknown.
In the current study, we hypothesized that prior pregnancy that results in priming of maternal lymphocytes to fetal antigen can impact development of tumors expressing the same antigen. To this end, we used chicken ovalbumin (OVA) as a surrogate-shared placenta/tumor antigen by mating males that transgenically express membrane-associated chicken OVA to wild-type (WT) C57BL/6J females. We first investigated the presence and persistence of endogenous maternal OVA-specific CD8+ T cells in OVA-mated dams; second, we investigated whether previously mated mice are susceptible to mouse lymphoma cells transduced to express OVA.
Materials and methods

Mice
All experiments were approved by the University of Kansas Medical Center (KUMC) Institutional Animal Care and Use Committee and were in accordance with National Institutes of Health Guidelines. C57BL/6J (B6) and C57BL/6-Tg (CAG-OVA)916Jen/J (Act-mOVA) mice were purchased from the Jackson Laboratory (Bar Harbor, ME) and maintained at the Laboratory Animal Resources Facility at the KUMC under pathogen-free conditions. Act-mOVA mice hemizygously express a transgenic construct encoding chicken OVA together with the leader sequence of the H-2K b gene and the transmembrane region of the H-2D b gene. Expression of this transgene occurs ubiquitously under the control of the chicken beta actin promoter together with the cytomegalovirus immediate-early enhancer. Mice were provided sterile food and water and were exposed to a 12L:12D photoperiod. OVA-transgenic offspring and implantation sites were identified by polymerase chain reaction (PCR) using the OVA-specific primers: oIMR3625 5 -TCC ATC GGC GCA GCA  AGC ATG GAA-3 and oIMR3626 5 -ATG TCT AGA AGG GGA  AAC ACA TCT GCC- loaded into each lane of a 4-15% Criterion (Bio-Rad) gel. Membranes were probed with rabbit antichicken OVA (1:4500; ab1221, Abcam, Cambridge, MA) and goat antimouse CD63 (200ng/ml; Santa Cruz Biotechnology, sc-31214), followed by the appropriate horseradish peroxidase-conjugated secondary antibody (1:20,000; Jackson ImmunoResearch). For immunoelectron microscopy, exosomes were fixed on formvar-carbon-coated grids and blocked for 1 h at room temperature with 5% bovine serum albumin (BSA), 1% donkey serum in PBS, and then incubated with mouse antichicken OVA (1:1000) overnight at 4
• C. After washing, grids were stained with 12 nm gold-conjugated donkey antimouse-IgG (1:40; ab105277, Abcam) for 1 h at room temperature. Following staining, grids were washed and incubated with 2.5% glutaraldehyde, contrasted with uranyl acetate, and imaged using a JEOL100 CXII transmission electron microscope.
Antibodies and flow cytometry
Primary antibodies and isotype controls directly conjugated to fluorophores are listed in Table 1 Cells were detected by flow cytometry using Streptavidin-APC (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA).
To identify and characterize fetal antigen-specific T cells in pregnant and parous dams, 6-8-week-old C57BL/6 females were bred to Act-mOVA transgenic males and sacrificed on GD 12.5 or 17.5, or 1, 8, or 15-24 weeks after pregnancy (n = 3-4/group). Gestational age-or postpregnancy-matched C57BL/6 females bred to WT C57BL/6 males served as experimental controls. Some mice were additionally treated with 100 μg of polyinosinic:polycytidylic acid (pI:C) (InvivoGen; Cat # tlrl-pic, San Diego, CA) or sterile saline (n = 6 per group) on GD12.5 and sacrificed on GD17.5. Splenic CD8 + T cells were prepared using a mouse CD8 + T cell enrichment kit (Stem Cell Technologies; Vancouver, BC), and 1 × 10 6 enriched cells were incubated with PE-labeled H-2K b -SIINFEKL pentamer (Proimmune;
Oxford, UK) for 10 min at room temperature. To control for nonspecific staining, 1 × 10 6 enriched CD8 + T cells were incubated in a separate tube with PE-labeled H-2K b -ATLTYRML pentamer (Proimmune). After incubation, all cells were washed once with 2 ml of PBS containing 0.1% BSA and 0.1% sodium azide (Wash buffer). Labeled cells were further incubated with a cocktail of primary antibodies to exclude nonspecifically bound cells for 20 min on ice. Finally, cells were washed twice with 2 ml wash buffer and fixed in PBS containing 2.5% formaldehyde and 1% heat-inactivated FBS in PBS. Data were acquired by flow cytometry within 2 days of staining using a LSRII cytometer, and analyzed using FACSDiva V5.0.2 software (BD Biosciences). At least 500,000 events were collected, and doublets were excluded from analysis by plotting side scatter area vs. width. CD19-negative, CD8-positive, SIINFEKL-H2Kb-positive cells were considered OVA specific.
Tumor experiments
For evaluating tumor growth in parous female mice, WT C57BL/6 females (n = 11) were bred to either Act-mOVA or WT males, allowed to deliver, and inoculated 8-9 weeks following delivery subcutaneously on the right hind flank with 1 × 10 6 E.G7-OVA lymphoma cells (ATCC, Cat# CRL-2113). Tumor volume was measured using a digital caliper three times per week (Mitutoyo, Kanagawa, Japan) until they reached 15 mm in any one diameter, at which time mice were sacrificed as mandated by KUMC animal care guidelines. Tumor volume (mm 3 ) was calculated by multiplying length, width, and height measurements. Virgin female mice (n = 11) served as additional tumor recipient controls.
In vivo cytotoxicity assay
For evaluating cytotoxic potential of OVA/H2K b -specific T cells in OVA-bred female mice, splenocyte target cells from C57BL/6 mice were either pulsed with OVA 257-264 (SIINFEKL) peptide (Proimmune, UK) or incubated in the absence of peptide (control) in RPMI medium containing 10% FBS and antibiotics for 1 h at 37
• C.
Peptide pulsed and control splenocytes were labeled with a high (2.5 μM) and a low (0.25 μM) concentration of carboxyfluorescein diacetate succinimidyl ester (CFSE; Molecular Probes), respectively. The differentially labeled cells were mixed in equal numbers, and a total of 5 × 10 6 cells in a volume of 100 μl were injected via tail vein into females previously bred to either Act-mOVA males (n = 8) or WT males (n = 5). Positive control mice were generated by immunizing WT females IP with 1 mg recombinant OVA (Sigma) together with 50 μg CD40 antibody (BioXcell; clone FGK4.5) and 50 μg Poly I:C. Mice from all three groups were sacrificed after seven days, and splenocytes were analyzed by flow cytometry for the presence of CFSE-labeled target and control cells, and the ratio (r) of target:control cells was calculated.
Statistical analysis
One-way analysis of variance was used to compare percent OVAspecific T cells during gestation and postpartum, for Poly I:C experiments and for comparing progression of tumors between OVA bred and controls. Survival curves were calculated using Kaplan-Myer survival analysis, and proportions of mice with tumors were analyzed by Chi-square test. Comparisons were made using Sigma-Stat software (version 3.5) or an online calculator (http://www.socscistatistics.com/). Differences of P < 0.05 are considered statistically significant.
Results
Placental exosomes carry membrane-associated OVA
Prior studies suggested that paternally inherited fetal OVA is crosspresented by maternal antigen presenting cells, and further, that maternal plasma contains placenta-derived exosomes carrying OVA [18] . In order to define whether OVA is associated with placental exosomes, we first purified exosomes from maternal plasma for immunoblot analysis. Consistent with the earlier report, paternally inherited OVA was detectable in pellets following centrifugation at 100,000 × g, in which exosomes are expected. Ovalbumin was detectable at GD12.5, 15.5, and 17.5, but not in unbred animals nor in animals 1 or 8 weeks following pregnancy ( Figure 1A and data not shown); additional nonspecific bands, which may represent proteins associated with either placenta-or maternally derived exosomes, were observed at ∼60-75 kD, as well as ∼25-30kD. Immunoelectron microscopy confirmed that OVA was associated with exosomes purified from supernatant of placentas of OVA+ pups, but not of WT pups, derived from mating of hemizygous OVA transgenic sires with WT dams ( Figure 1B ).
Maternal antifetal ovalbumin-specific T cells are elicited during pregnancy and can persist following delivery
In both women and mice, endogenous T cells can be primed to paternally inherited fetal antigen [8] . Additionally, others have shown that the surrogate paternally inherited antigen, OVA, is cross-presented by maternal antigen presenting cells to adoptively transferred T cells during pregnancy [19] . To determine whether gestational exposure to fetal OVA can sensitize endogenous maternal CD8 + T cells, we mated hemizygous OVA transgenic male mice with WT females such that on average half of the fetuses inherit and express OVA. Flow cytometric analysis of splenocytes from pregnant GD17.5 OVA-bred female mice revealed the presence of OVA-specific T cells during pregnancy; no OVA-specific T cells were detected in WT-bred control mice (Figure 2A) . To understand the kinetics of this endogenous response, OVA-bred female mice were sacrificed during gestation at GD12.5, GD17.5, or 1, 8, or 15-24 weeks following pregnancy. Ovalbumin-specific T cells could be detected at both 12.5 and 17.5 of gestation ( Figure 2B ), and in some mice could be detected up to 24 weeks following gestation. The expression of CD44 on these cells confirms that these cells have encountered OVA antigen, and suggests an activated or memory phenotype. During pregnancy, OVAspecific T cells were detected in all of mice examined (n = 7); proportion of OVA-specific T cells among total CD8+ cells in OVA-bred mice ranged from 0.003% to 0.09%. The proportion of mice with OVA-specific cells progressively declined following pregnancy (Figure 3A) , as did average numbers of cells per mouse ( Figure 3B ). Together, these data reveal that an immune response to fetal antigen is elicited during pregnancy and that these fetal antigen-specific T cells can persist long-term after delivery.
The endogenous response to ovalbumin during pregnancy remains unaltered during an inflammatory stimulus
To determine whether an inflammatory stimulus during pregnancy alters the endogenous response to OVA, we mated OVA males to WT females, and on GD12.5 pregnant females were injected with either 100 μg of pI:C or saline (vehicle). Five days following injection, the mice were sacrificed and OVA-specific T cells were quantified by flow cytometry. Anti-OVA T cells ranged from 0.0172% to 0.147% of total CD8 T cells in pI:C group, and did not vary significantly as compared to the control mice (P = 0.315) ( Figure 4A and B) .
Additionally, the proportion of OVA-specific T cells in dams was independent of the number of OVA-positive implantation sites, based on 11 litters of 2-6 (OVA+ fetuses (22-72% of total fetuses; Figure 4C) ). To characterize the phenotype of anti-OVA T cells from both the treatment groups, enriched CD8 + T cells were incubated with a cocktail of primary antibodies (CD44, CD8, CD19, PD-1, ICOS, and CD69). Expression of these markers among total CD8+ cells did not differ significantly between groups (CD44: 97.325 ± 1.302% vs. 99.56 ± 0.328%; PD-1: 12.1 ± 3.195% vs. 15.75 ± 3.72%; CD69: 14.675 ± 1.23% vs. 18.033 ± 3.64%; ICOS: 23.9 ± 4.52% vs. 18.583 ± 5.84%, in saline and Poly I:C-injected animals, respectively).
Prolonged tumor-free survival and delayed progression of tumors in ovalbumin-bred mice
Our initial experiments show that fetal OVA elicits a T cell response during gestation and that anti-OVA T cells can persist in dams long term. We next asked whether these antigen-specific T cells could have any functional relevance to maternal health following pregnancy. Specifically, we hypothesized that prior pregnancy with antigenic OVA-bearing fetuses would impact tumor progression of cancers also bearing OVA antigen. To test this, we subcutaneously injected ACT-mOVA-mated or WT-mated females at 8-9 weeks following pregnancy with E.G7-OVA lymphoma cells, which constitutively express OVA and present the antigen in the context of H2K b ( Figure 5D ) [17] . Wild-type-bred females and virgin females served as controls. Of 11 OVA-bred mice, seven (64%) developed detectable tumors as compared to 10 of 11 (91%) mice in both the virgin and B6-bred groups. The mean number of days to onset of tumors among OVA-bred mice did not differ significantly as compared to B6-bred mice or virgin controls (P > 0.05). However, the kinetics of tumor growth differed between groups. Of seven OVA-bred mice with tumors, three (42.8%) developed tumors to a size of 15 mm in diameter, at which time the mice were sacrificed due to tumor burden. Four of 10 (40%) and six of 10 (60%) B6-bred and virgin mice, respectively, met this end-point ( Figure 5A ). Additionally, exponential growth of tumors in OVA-bred mice occurred only after 40 days postinoculation, whereas exponential tumor growth in both B6-bred and virgin mice began prior to 40 days ( Figure 5A ). OVA-bred mice also remained tumor free for longer as compared to virgin mice (P = 0.017) ( Figure 5B ). Of the mice that ultimately developed terminal tumors, those that bore OVA-expressing litters had prolonged survival (67.3 ± 2.18 days) as compared to mice that bore WT litters (38.25 ± 6.60 days; P = 0.01) or virgin mice (32.83 ± 3.1 days; P = 0.007). Kaplan-Meier analysis revealed a significant difference in survival time of OVA-bred mice as compared to virgin mice (P < 0.05) ( Figure 5C ).
OVA-specific T cell cytotoxicity in OVA-bred mice
Because OVA-bred mice showed prolonged survival and delayed progression of tumors and the persistence of OVA-specific T cells, we performed an in vivo cytotoxicity assay to assess whether OVAspecific T cells in parous mice exhibit cytotoxic activity. Eight weeks after pregnancy, OVA-bred mice were injected with SIINFEKLpulsed and unpulsed control CFSE-labeled splenocytes. Wild-typebred mice and OVA-inoculated mice served as negative and positive controls, respectively. As expected, OVA-inoculated mice illustrated high levels of cytotoxicity; CFSE (high)-labeled, SIINFEKL-pulsed cells became undetectable ( Figure 6A and B) . Additionally, none of the B6-bred mice showed OVA-specific cytotoxicity. However, three of eight (37.5%) OVA-bred mice showed an intermediate response, with cytotoxicity ranging from 50% to 75%. These results show that some mice retain in vivo cytotoxic T cell activity specific for cells expressing fetal antigen for at least eight weeks following gestation.
Discussion
The maternal immune system has been shown previously to elicit both humoral [20] [21] [22] and cellular [8, 11, 12, 23] immune responses toward paternally inherited antigens during pregnancy. Using paternally inherited OVA as a model shared placenta/tumor-associated antigen, we show for the first time that, in mice, the surrogate antigen OVA can elicit an endogenous maternal CD8+ T cell response, and further, that responding T cells persist for months following pregnancy. These cells likely occur as a result of OVA expression at the maternal-fetal interface, release into the maternal blood via exosomes and its subsequent cross-presentation by maternal antigen presenting cells [19, 23] . Additional possibilities for exposure of fetal antigen to the maternal blood include release of microvesicles and microchimerism, in which fetal and/or placental cells traffic into maternal organs [24] . Although our data contrast with a previous report that OVA does not elicit maternal CD8+ T cells [18] , they parallel prior observations that in women, maternal T cells are generated as a result of fetal exposure during pregnancy, and further, that they can persist long-term, even years following pregnancy [10, 12] . Importantly, the health impact of these cells on maternal health has not been previously examined. The data presented here establish the paternally inherited OVA mating system as a useful model for studying the pathophysiological impact of fetus-specific maternal T cells on maternal health, long after gestation. To begin to understand how maternal antifetal T cells might impact maternal longer term health, we used fetal/placental OVA as a surrogate antigen with an expression pattern that anatomically mimics the expression of human shared tumor-placenta antigens. In mice, placental OVA expression localizes to several cell populations including labyrinthine trophoblast cells, which line maternal blood spaces. In the human placenta, the tumor antigens 5T4, MAGE-A3, MAGE-A4, and NY-ESO-1 are expressed in the syncytiotrophoblast, which also lines the maternal blood space [14, 16] . In both species, the juxtaposition of antigen-expressing trophoblast cells with maternal blood may be important for exposure of the maternal immune system to fetal antigen, as maternal blood is a likely conduit for fetal antigen [25] . Further, in our explant model, we observed that OVA is associated with the surface of exosomes by immunoelectron microscopy. A limitation of this approach is that, in our system, explants underwent some degree of cell death as assessed by histolologic analysis (data not shown). However, the advantage of this system is that it allows isolation of high quantities of relatively pure placenta-derived exosomes, whereas direct purification of exosomes from maternal plasma would result in a mixture of maternal and placental vesicles, likely with the majority being maternally derived [26] . Further, we were able to detect OVA protein when EVs were purified from maternal plasma, consistent with release into maternal blood in association with exosomes. Further studies are required to determine whether placental expression of these antigens during pregnancy elicits maternal T cells in women. However, the studies presented here demonstrate proof-of-principle that fetal antigen-specific maternal immune responses could influence subsequent nonpregnancy-associated responses to the same antigens, namely during cancer development.
From an immunological perspective, tumor-associated antigens can be considered tumor-specific targets due to either their absence or minimal expression on normal adult tissues. Notable exceptions to this restricted expression include the cancer-testes antigens and the oncofetal antigens, several of which are expressed in the testis, placenta, or both. In common, these tissues are characterized by highly restricted expression of Human Leukocyte Antigen (HLA) class I and class II molecules; thus, antigen presentation by their cells is limited or precluded [27] . Furthermore, their limited expression together with their ability to stimulate a cytotoxic T cell response makes these antigens attractive candidates as targets for cancer immunotherapy [28, 29] .
Prior studies have demonstrated that adoptively transferred T cells can respond to paternally inherited fetal OVA [19] ; here, we found that endogenous OVA-specific T cells are detected in the spleen by day 12.5 of gestation. It is also likely that fetal antigen-specific T cells are present in the uterus-draining, and even nondraining lymph nodes, as antigen presentation and T cell responses can be detected at these sites in pregnancy, possibly reflecting lymphatic, in addition to hematogenous, drainage of fetal antigen [19, 23, 30] . In women, fetal antigen-specific T cells are detectable from first trimester onwards [12] , despite a lack of direct connection between maternal blood flow and the placenta. Further, HY-specific T cells were detected in 45% of women with a male fetus postpartum [12] , an observation in line with our observations in this study.
It has been reported that OVA immunization prior to OVA mating, and further re-immunization during early pregnancy does not affect fetal viability [31] . Interestingly, an inflammatory stimulus during gestation does not enhance the endogenous response to OVA. A critical question that arises is the mechanism of suppression of the endogenous response to fetal antigens, even in the presence of adjuvant. Although immunomodulatory costimulators such as ICOS and PD-1 have been implicated in protection of the semiallogeneic fetus in pregnancy, these molecules may be more important in regulating CD4+ T cell responses; indeed, these proteins were not upregulated on endogenous CD8+ T cells [32] . Others have observed similar responses by transferred T cells in the presence of adjuvant, and implicated that shed OVA from the placenta may play an important role in targeting a subset(s) of antigen presenting cells [18] . Here, we show that OVA is present on exosomes derived from the serum of OVA-mated dams, raising the possibility that exosome-associated fetal antigen is in some way immunosuppressive. This would be in line with observations in human studies, in that placental exosomes and microvesicles appear to be immunosuppressive and possess suppressive ligands [33, 34] . We next sought to understand implications of long-term persisting antifetal T cells in mothers. In women, these cells have been suggested to possess cytotoxic activity in vitro, although detection and functional analysis most often requires antigen-stimulated expansion [12] , which may result in nonphysiological activity and/or phenotype. However, studies have implicated fetal antigen-specific immune cells in graft vs. host and graft vs. leukemia effects following bone marrow transplantation from parous donors [35] [36] [37] . In order to deduce possible in vivo functional activity of these T cells, we took the advantage of an OVA-expressing murine tumor cell line. The fact that 36% of OVA-bred mice remained tumor free for up to 100 days following pregnancy, and that OVA-bred mice with tumors progressed more slowly than WT-bred or virgin animals, suggests a protective effect of pregnancy mediated by OVA-specific immunity. Furthermore, in vivo cytotoxicity assay showed that 37% of OVA-bred mice showed a cytotoxic response toward antigen-pulsed target splenocytes, confirming that these cells retain some cytotoxic activity in vivo against cells outside the uterus following pregnancy. This proportion closely aligns with the percentage of OVA-bred mice that remained tumor free, as well as those that retained fetal antigen-specific T cells. These results are reminiscent of the ability of the maternal immune system to eliminate Major Histocompatibility Complex (MHC) incompatible fetal microchimeric cells following pregnancy [38] . Tumor cells, including those used in our study, produce copious amounts of exosomes in vivo (Petroff and Farahbakhsh, unpublished observation), which can be cross-presented by dendritic cells to T cells [39] . However, it seems likely that direct targeting of tumor cells by OVA-specific T cells that arose during pregnancy could also occur. EG.7-OVA lymphoma cells express surface H-2K b and present SIIFEKL peptide, thus providing an appropriate targeting ligand for cytotoxic T cells. Further, maternal OVA-reactive lymphocytes arising from pregnancy appear to retain cytotoxic capability, as suggested by the in vivo cytotoxicity assay. Also, in preliminary experiments we observed infiltration of OVA-specific CD8+ T cells into tumors of mice that had borne OVA-expressing fetuses (Jasti and Petroff, unpublished). While additional controls, such as MHC-or OVA-negative tumor induction, are required to determine whether this response is specific or heightened in comparison to B6-bred or nonparous mice, the data obtained thus far point to a role for direct presentation of tumor antigen by the tumor cells. Other studies have examined the effect of pregnancy on immunological priming to both skin grafts and tumors bearing paternal major and minor histocompatibility antigens, collectively pointing to either sustained tolerance [8, 40, 41] or immunity [42] to these antigens upon re-exposure outside the context of pregnancy. Cancer antigens may be comparable to minor antigens in terms of the mechanisms by which they may prime the maternal immune system, with a key difference being that instead of being inherited, they are placenta specific. James et al. reported that multiparity can induce tolerance to paternally inherited minor antigens when parous females were reexposed to fetal antigen via a skin graft [8] , while our results suggest immunity to tumors. The reason for this difference is not clear, but it is possible that increasing parity gradually induces tolerance via progressive accumulation of regulatory T cells [41, 43] . Additionally, the surgical process of grafting likely causes elaboration of danger signals more so than injection of tumor cells does [44] , potentially leading to different outcomes. Finally, epidemiological studies of graft vs. host disease suggest that multiparity induces immunity to antigens shared by the fetus, making parous women suboptimal donors for hemotopoietic stem cell transplantation [35] [36] [37] 45] . Clearly, there are multiple factors at play that deserve more investigation into this important question.
Additional immunologic mechanisms not examined here may contribute toward altering cancer risk following pregnancy, including altered function of Natural Killer (NK) cells, B cells, and antigen presenting cells. These possibilities deserve further investigation in the study of antitumor immunity in new murine models as well as in women. Additionally, women with hypertensive disorders during pregnancy were reported to have significantly lower risk of breast and lung cancer [46] ; whether longer term exposure of maternal immune cells in an inflammatory environment provides augmented protection warrants further investigation. Collectively, our data shed light on a new mechanism of immunity generated during pregnancy that has potential for exploitation in cancer immunotherapy, specifically, ex vivo expansion, and transfer of autologous antitumor T cells.
